



Death from Neglected Pituitary Adenoma: A Case Report

G. A. Ebughe^{1*} and T. I. Ugbem¹

¹*Department of Pathology, University of Calabar, Nigeria.*

Authors' contributions

This work was carried out in collaboration between both authors. Author GAE designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Author TIU managed the analyses of the study. Author TIU managed the literature searches. Both authors read and approved the final manuscript.

Article Information

DOI: 10.9734/IJTDH/2019/v38i230182

Editor(s):

(1) Dr. Thomas I. Nathaniel, Department of Biomedical Sciences, School of Medicine-Greenville, University of South Carolina, USA.

Reviewers:

(1) Luis Rafael Moscote-Salazar, University of Cartagena, Colombia.

(2) Gerardo Caruso, University of Messina, Italy.

(3) Muhammad Muizz Uddin, Dow University of Health Sciences, Pakistan.

Complete Peer review History: <http://www.sdiarticle3.com/review-history/51209>

Case Report

Received 12 June 2019
Accepted 26 August 2019
Published 30 August 2019

ABSTRACT

We present a case of a patient who presented with pituitary macroadenoma complicated with hydrocephalus. He presented late to the referral hospital in a comatose state and died a few hours later. He was a 33-year-old, male who gave a history of highly accelerated symptoms lasting 1 week. Neurosurgical consultation as well as investigations with CT scan or MRI were not availed the patient, which could have been life saving. Autopsy findings were of a pituitary macroadenoma and signs of hydrocephalus and raised intracranial pressure which proved fatal.

Keywords: Pituitary; adenoma; hydrocephalus.

1. INTRODUCTION

Pituitary adenomas (PA) are intracranial tumours that may result in death [1]. Autopsy studies

suggest that microadenomas (<10mm) occur in 10 to 20% of the population [2,3], while macroadenomas >10 mm are quite rare [4,5]. PA commonly produce ocular, or endocrine

*Corresponding author: Email: gobeng02@gmail.com;

symptoms [6], others symptoms relate to mass effect as well as obstruction to cerebrospinal fluid(CSF) flow. Giant PA ≥ 4 cm have been reported [7-10]. PA occur mostly in adults, but a case in infancy resulting in sudden death was reported [11]. Equally occurrence in paediatric age range as well as adolescents [12,13] are reported. PA account for 10% of intracranial neoplasms, and most of these arise from the adenohypophysis, other sites are involved by extension, infiltration or ectopic location [14,15]. PA present a challenge to the clinician in determining the clinical significance, appropriate diagnosis, need for treatment and type of therapies/therapies [16]. PA may be functional (FA) or non-functional (NFA). Functional adenoma may produce a single hormone such as growth hormone (GH) secreting somatostatinomas, prolactin (PRL) prolactinomas, adrenocorticotrophic hormone (ACTH) corticotrophinomas, thyroid stimulating hormone(TSH) thyrotropinomas [17,18] and other rare hormone products [19] or mixed hormones [20]. Clinical presentations may range from acromegaly or gigantism [21], Cushing's syndrome [22], Nelson syndrome, hyperprolactinaemia, and other rare endocrine syndromes. Most cases are sporadic, but some occur as part of multiple endocrine neoplasia 1 [23,24], or other inheritable tumour syndromes [25], and may occur with other tumours [26,27].

Mortality in the NFA adenoma is commonly due to hormone deficiency, surgery, and mass effect as they often grow very large before detection [28,29]. In one series patient died of circulatory complications, respiratory complications as well as infections [28], and in another series patients suffered occult hydrocephalus, and they died of complications following repeated interventions [30]. The common presentation of NFA remain, headaches visual disturbance and the hormonal deficiencies [31]. Among the functional adenomas (FA), mortality from vascular disease is the predominant cause of death [28]. In ACTH producing adenomas, control of cortisol and growth hormone secretion limits the cardiovascular risk [28]. Pituitary apoplexy is a sudden vascular event in a PA that can also be life threatening [32,33], and has been reported to induce severe intracerebral haemorrhage [34,35], and death [36]. Cases of hydrocephalus complicating PA were successfully treated through neurosurgical shunt procedures [37,38]. In our environment an interplay of sociocultural and adverse economic factors frequently stand in the way of clinical care leading to disastrous

consequences for patients. It is common to see patients consult traditional medicine practitioners due to cultural and economic considerations, only to appear for orthodox medical care when it is very late.

2. CASE REPORT

We present the case of a 33-year-old man with a history of headache of seven days duration.

Blurring of vision of 2 days, seizures which were intermittent and unconsciousness of a day's duration.

The headache was of sudden onset, noticed on the right temporal area and later became generalized. Described as the worse headache he has ever suffered. No known aggravating or relieving factor. Pain was said to radiate to the neck. Patient was initially ambulant but later could not undertake normal activities and could not sleep. There was no fever or associated but vomited repeatedly. The vomitus was non projectile, or bilious and comprised of recently ingested feeds.

He then developed tonic clonic seizure with an episode lasting 2 minutes, terminating in a cry and urinary incontinence.

Patient lapsed into unconsciousness on the way from the point of first consultation to the referral centre in the teaching hospital.

His past medical history was not contributory.

He was not known to indulge in alcohol or tobacco use. There was no previous history of hypertensive or diabetes mellitus, and had not recently travelled to the meningitis belt of the country.

Physical examination revealed a young man gasping for breath, was on oxygen at the time of reception at the referral hospital.

3. CNS EXAMINATION

He was unconscious with a Glasgow coma scale of 3/15 distributed as spontaneous eye movement(E1), verbal response(V1), motor response(M1).

Pupils were 5 cm dilated and fixed, non-reactive to light (direct and consensual).

The neck was supple, Kernig's and Brudzinski signs were negative.

Cranial nerves 11, 111, 1V, V11, 1X, X were non responsive.

Muscle tone was reduced in all the limbs. Muscle power could not be assessed objectively.

There was generalized depression in limbs reflexes, both plantar and flexor.

4. RESPIRATORY SYSTEM

The respiratory rate RR: was 42 cycles per minute and was gasping. The chest was resonant and breath sounds were vesicular.

5. CARDIOVASCULAR SYSTEM

Pulse rate was 140 bpm, small volume. The apex beat, was at the normal position, jugular venous pressure was not raised.

The blood pressure progressively fell from 120/60 mmHg on admission at 9am to being unrecordable at 12 noon.

Examination of the other organ systems did not reveal any significant find.

6. PRESUMPTIVE DIAGNOSIS

- (1) Subarachnoid haemorrhage secondary to ruptured aneurism.
- (2) Space occupying lesion (Glioma).

Patient was admitted into the intensive care unit under the neurology unit.

7. INVESTIGATIONS AND RESULTS

- (1) Random blood sugar RBS 12.4 mmol/l.
- (2) Urinalysis was normal.
- (3) HIV screening was Negative.
- (4) Complete blood count: Total wbc 5×10^4 /dl, Lymphocytes 47%, Neu .50%, eos .1% Platelets; in normal range.
- (5) Serum electrolytes: Sodium: 130 mm/l, Potassium. 3.3 mm/l calcium, magnesium and creatinine were being processed before patients' demise.
- (6) Skull X ray was ordered but was not done because the patient was very unstable.
- (7) Cranial CAT scan and MRI were, ordered but were not done before patient passed.



Fig. 1. Left cerebral hemisphere showing a pituitary adenoma and markedly enlarged lateral ventricle

8. TREATMENT

- (1) 20% Mannitol 250 ml over 4 hours, every 8 hrs. for 72 hrs.
- (2) Normal saline 1 litre 8 hourly for 72 hours.
- (3) Intravenous frusemide 20 litres after each dose of mannitol.
- (4) Monitoring of vital signs every 30 minutes.
- (5) Strict monitoring of fluid input and output.

9. OUTCOME

Patients died within two hours. Autopsy was ordered for.

10. AUTOPSY FINDINGS

Patient was generally well nourished looking, male, 1.62 m in height and weighing 72 kg. The pupil were dilated and fixed. Other physical examinations carried out were found to be in the normal range.

The main autopsy findings were in the central nervous system (CNS) and the bones surrounding the sella tursica. The brain weighed 1350g, The gyri were flattened bilaterally and the sulci narrowed. There was bilateral uncal and cerebellar tonsillar grooving. A large pituitary tumour measuring 3.4 x 2 x 2 cm was found completely occluding the 3rd ventricle and projecting into the lateral ventricles. The lateral ventricles were dilated on both sides, the left measuring 12 cm long and 8 cm in the widest portion. The right measured 12 cm long and 7cm in the widest portion. The bones of the sella tursica were significantly eroded, but the tumour was still covered by the diaphragma sella and the carvenous sinus had not been eroded into.

A diagnosis of Pituitary adenoma causing Hydrocephalus was made.

The cause of death was concluded to be coning due to hydrocephalus, which in turn was induced by a pituitary adenoma.

11. DISCUSSION

Although the patient history suggested a symptom duration of 1 week, the findings at autopsy suggested otherwise. It is very likely that the pituitary adenoma had been for a while inducing symptoms which were not heeded to until it became too late. Adenomas that grow very large tend to be the non-functional types

[6,28] in most cases, although one series in the United States reported 5 giant prolactinomas in [7]. Patients with the functional adenomas normally seek medical attention quicker because of the endocrine symptoms they induce [16]. Our index patient had no hormonal assay or immunohistochemistry to determine if the PA was functional or not. There was however raised random blood sugar which may suggest hypercortisolism, or even raised thyroid hormones. It is also important to state that the types of resources needed to save this patient are currently not in our centre. Early presentation would still have been beneficial to the patient because our hospital operates a robust referral system which would have been activated to save the patient's life. The lessons to learn in this case is the need for early hospital consultation when seemingly ordinary symptoms such as persistent headaches, blurring of vision are encountered. In our country the alternative medical practitioners often act as a barrier between patients and orthodox medical consultations, often with disastrous consequences.

12. CONCLUSION

This case highlights the common practise of patents arriving late for hospital treatment. Although the patient would have still had a tough time accessing the kind of care that will bring relief in this case. Government should intervene to change the circumstances that will improve patients welfare.

CONSENT

Patients personal data was anonymised and permission for the use of specimen photographs was granted by the Department of Pathology, University of Calabar Teaching hospital.

ETHICAL APPROVAL

There were no ethical issues in this case and permission to report this case was granted by the institutional review board.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Wang AR, Gill JR. The pituitary gland: An infrequent but multifaceted contributor to

- death. *Acad Forensic Pathol.* 2016;6(2): 206-16.
2. Stadnik T, Spruyt D, van Binst A, Luybaert R, d'Haens J, Osteaux M. Pituitary microadenomas: diagnosis with dynamic serial CT, conventional CT and T1-weighted MR imaging before and after injection of gadolinium. *Eur J Radiol.* 1994; 18(3):191-8.
 3. Scanarini M, Mingrino S, Boscaro M, Sicolo N, Serafini E, Billeci D. Pituitary microadenomas: Surgical results and morphological findings. *Acta Neurochir (Wien).* 1983;69(3-4):231-42.
 4. Molitch ME, Russell EJ. The pituitary "incidentaloma". *Ann Intern Med.* 1990;112 (12):925-31.
 5. McNicol AM, Walker E, Farquharson MA, Teasdale GM. Pituitary macroadenomas associated with hyperprolactinaemia: immunocytochemical and in-situ hybridization studies. *Clin Endocrinol (Oxf).* 1991;35(3):239-44.
 6. Goldstein JE, Sherman JF. Pituitary adenoma. *Optom Clin.* 1993;3(3):101-25.
 7. Madsen H, Borges TM, Knox AJ, Michaelis KA, Xu M, Lillehei KO, et al. Giant pituitary adenomas: Pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling. *Am J Surg Pathol.* 2011;35(8):1204-13.
 8. Siddiqui AA, Bashir SH. Giant pituitary macroadenoma at the age of 4 months: case report and review of the literature. *Childs Nerv Syst.* 2006;22(3):290-4.
 9. Goel A, Nadkarni T, Muzumdar D, Desai K, Phalke U, Sharma P. Giant pituitary tumors: A study based on surgical treatment of 118 cases. *Surg Neurol. Discussion* 45-6. 2004;61(5):436-45.
 10. Barrera CM, Ruiz AE, Banks WA. A giant prolactinoma and the effect of chronic bromocriptine therapy on basal and TRH-stimulated serum prolactin levels. *Horm Res.* 1991;35(3-4):167-9.
 11. Matsuura H, Kitazawa Y, Tanaka M, Morooka K. Pituitary adenoma and unexpected sudden infant death: A case report. *Med Pediatr Oncol.* 1994;22(4):283-6.
 12. Kanter SL, Mickle JP, Hunter SB, Rhoton AL. Pituitary adenomas in pediatric patients: Are they more invasive? *Pediatr Neurosci.* 1985;12(4-5):202-4.37
 13. Ortiz-Suarez H, Erickson DL. Pituitary adenomas of adolescents. *J Neurosurg.* 1975;43(4):437-9.
 14. Wong K, Raisanen J, Taylor SL, McDermott MW, Wilson CB, Gutin PH. Pituitary adenoma as an unsuspected clival tumor. *Am J Surg Pathol.* 1995;19 (8):900-3.
 15. Platta CS, Mackay C, Welsh JS. Pituitary adenoma: a radiotherapeutic perspective. *Am J Clin Oncol.* 2010;33(4): 408-19.
 16. Vance ML. Pituitary adenoma: a clinician's perspective. *Endocr Pract.* 2008;14(6):757-63.
 17. Oruckaptan HH, Senmevsim O, Ozcan OE, Ozgen T. Pituitary adenomas: results of 684 surgically treated patients and review of the literature. *Surg Neurol.* 2000; 53(3):211-9.
 18. Linquette M, Herlant M, Fossati P, May JP, Decoulx M, Fourlinnie JC. [Pituitary adenoma with thyrotropic cells with hyperthyroidism]. *Ann Endocrinol (Paris).* 1969;30(6):731-40.
 19. Esiri MM, Adams CB, Burke C, Underdown R. Pituitary adenomas: immunohistology and ultrastructural analysis of 118 tumors. *Acta Neuropathol.* 1983;62(1-2):1-14.
 20. Oda S, Wada Y, Kondo H, Ishikawa Y, Kadota K. Pituitary adenoma with prolactin and growth hormone production in a sheep. *J Comp Pathol.* 1997;117(2):171-5.
 21. Zang X, Zhang SY, Zhang SH, Lu YJ, Wang WJ, Yin ZY, et al. Pituitary adenomas with acromegaly. Light microscopic and electron microscopic study of 60 cases. *Chin Med J (Engl).* 1983;96(9):647-54.
 22. Raffel C, Boggan JE, Eng LF, Davis RL, Wilson CB. Pituitary adenomas in Cushing's disease: Do they arise from the intermediate lobe? *Surg Neurol.* 1988;30 (2):125-30.
 23. Dralle H, Altenahr E. Pituitary adenoma, primary parathyroid hyperplasia and papillary (non-medullary) thyroid carcinoma. A case of multiple endocrine neoplasia (MEN). *Virchows Arch A Pathol Anat Histol.* 1979;381(2):179-87.
 24. Scheithauer BW, Laws ER Jr, Kovacs K, Horvath E, Randall RV, Carney JA. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. *Semin Diagn Pathol.* 1987;4(3):205-11.
 25. Nakajima M, Nakasu Y, Nakasu S, Matsuda M, Handa J. [Pituitary adenoma associated with neurofibromatosis: case report]. *Nihon Geka Hokan.* 1990;59(3): 278-82.

26. Gokden M, Mrak RE. Pituitary adenoma with craniopharyngioma component. *Hum Pathol.* 2009;40(8):1189-93.
27. Xekouki P, Szarek E, Bullova P, Giubellino A, Quezado M, Mastroyannis SA, et al. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. *J Clin Endocrinol Metab.* 2015;100(5):E710-9.
28. Tampourlou M, Fountas A, Ntali G, Karavitaki N. Mortality in patients with non-functioning pituitary adenoma. *Pituitary.* 2018;21(2):203-7.
29. Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, et al. Mortality in patients with pituitary disease. *Endocr Rev.* 2010;31(3):301-42.
30. Crowley Hasajn. Hydrocephalus complicating pituitary adenoma. *Journal of Neurology, Neurosurgery and Psychiatry.* 1973;36:1063-8.
31. Danfeng Zhang JC, Zhenxing Li, Junyu Wang, Kaiwei Han, Lijun Hou. Clinical features and management of nonfunctioning giant pituitary adenomas causing hydrocephalus. *Oncotarget.* 2018; 9(20):15409-17.
32. Yoshino M, Sekine Y, Koh E, Hata A, Hashimoto N. Pituitary apoplexy after surgical treatment of lung cancer. *Ann Thorac Surg.* 2014;98(5):1830-2.
33. Yang MH, Chuang H, Jung SM, Van YH, Lo FS. Pituitary apoplexy due to prolactinoma in a Taiwanese boy: Patient report and review of the literature. *J Pediatr Endocrinol Metab.* 2003;16(9): 1301-5.
34. Nakahara K, Oka H, Utsuki S, Iida H, Kurita M, Mochizuki T, et al. Pituitary apoplexy manifesting as diffuse subarachnoid hemorrhage. *Neurol Med Chir (Tokyo).* 2006;46(12):594-7.
35. Kurisu K, Kawabori M, Niiya Y, Ohta Y, Mabuchi S, Houkin K. Pituitary apoplexy manifesting as massive intracerebral hemorrhage. Case report. *Neurol Med Chir (Tokyo).* 2012;52(8):587-90.
36. Gruber A, Clayton J, Kumar S, Robertson I, Howlett TA, Mansell P. Pituitary apoplexy: Retrospective review of 30 patients--is surgical intervention always necessary? *Br J Neurosurg.* 2006;20(6): 379-85.
37. Crowley Hasajn. Hydrocephalus complicating pituitary adenoma. *Journal of Neurology, Neurosurgery and Psychiatry.* 1973;36:1063-8.
38. Danfeng Zhang JC, Zhenxing Li, Junyu Wang, Kaiwei Han, Lijun Hou. Clinical features and management of nonfunctioning giant pituitary adenomas causing hydrocephalus. *Oncotarget.* 2018; 9(20):15409-17.

© 2019 Ebughe and Ugberm; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<http://www.sdiarticle3.com/review-history/51209>